Spirometer Market Size, Share & Industry Analysis, By Product Type (Devices, Software, and Accessories & Consumables), By Type (Volume Measurement and Peak Flow Meters), By Application (Chronic Obstructive Pulmonary Disorder (COPD), Asthma, and Others), By End User (Hospitals, Diagnostic Centers, Homecare Settings, Physician/Primary Care Offices or Clinics, and Other Facilities), and Regional Forecast, 2024-2032

The global spirometer market size was valued at USD 613.3 million in 2023. The market is projected to grow from USD 645.5 million in 2024 to USD 997.9 million by 2032, exhibiting a CAGR of 5.6% during the forecast period. North America dominated the spirometers market with a market share of 50.3% in 2023.

The spirometer is a diagnostic device used for measuring the air volume inspired and expired by the lungs. It is used to diagnose asthma, chronic obstructive pulmonary disease (COPD), and other conditions that affect breathing. Spirometry is the basic lung function test required to diagnose and treat COPD, asthma, and other respiratory disorders. According to the Forum of International Respiratory Societies (FIRS) 2023 statistics, chronic respiratory diseases cause an immense worldwide health burden. It has been estimated that around 334 million people have asthma, while more than 65 million people suffer from COPD. In addition, asthma is the most common cause of respiratory illness, affecting 14% of children globally and number is rising.

Moreover, public and private organizations are collaborating to develop devices for managing and diagnosing respiratory diseases such as COPD and asthma. In addition, the market players are actively investing in introducing technologically advanced devices and software to surge the demand for these products. For instance, in January 2023, Aluna completed a USD 15.3 million Series B round of financing to continue the growth of its solution, which is a spirometer device and easy-to-use app for managing asthma, cystic fibrosis, and COPD.

Furthermore, the COVID-19 outbreak impacted the global market negatively owing to a decline in the diagnosis and treatment of respiratory diseases. The majority of pulmonary function tests (PFTs) labs and testing centers were closed in the potentially affected areas. In 2021, as the lockdown restrictions were eased with the resumption of healthcare facilities, the supply of these devices witnessed a surge at the global level. The growth was observed in the revenues of market players with increasing sales of medical devices in 2022. Moreover, the market is anticipated to grow steadily during the forecast period owing to increased test volume measurement and the demand for these devices.

Spirometer Market Trends

Growing Investment Opportunities to Drive Market Growth

Owing to the growing demand for accurate devices for lung function assessment, the major players are focusing on investments to develop advanced devices. Various established players and new start-ups seek funding to carry out research and hospital and clinical testing of pulmonary testers.

• For instance, In June 2021, NuvoAir, a Stockholm-based digital health company, raised USD 12 million to expand its chronic disease management and clinical trial platforms. The funding was directed by AlbionVC and comes on the back of a record 500% growth for the first quarter of 2021. The platform's technologies comprise Bluetooth-enabled spirometers that can be used to monitor lung function remotely, a sensor connected to asthma and COPD inhalers, and Fitbit integration.

Moreover, government and private organizations such as the National Science Foundation and the European Union Horizon Program are actively collaborating with research institutes and start-ups to develop devices for the management and diagnosis of respiratory diseases such as COPD and asthma.

• For instance, in July 2020, NanoVation, a start-up company involved in developing devices for COPD patients, received a grant worth USD 2.0 million from the European Union’s Horizon 2020 EIC Accelerator program for their SenseGuard device. This device is based on nano-sensor technology, which is wearable and used to monitor patients' breathing continuously. Such initiatives by the industry players are anticipated to boost the spirometer market growth.

Furthermore, there is an increase in research and development activities in launching smart spirometer devices and remote monitoring to improve patient outcomes with asthma and COPD. The introduction of a smart spirometer for monitoring a patient's lung function and adjusting treatment as needed resulted in a notable decrease in asthma-related visits to the emergency department and hospitalizations. Such trends lead to the expansion of the global spirometer market during the forecast period.

Request a Free sample to learn more about this report.

Spirometer Market Growth Factors

Increasing Technological Advancement in Diagnostic Tools to Proliferate Market Growth

Lung function tests are essential to evaluate the core functioning of the lungs. By assessing PFTs, which include lung volumes, lung capacities, rates of flow, and gas exchange, physicians get the information that aids in diagnosing multiple lung disorders, especially COPD. High investments by the key market players for the extensive research and development of novel and advanced diagnostic and monitoring technologies are expected to enable the early diagnosis of COPD. Thus, technological developments are expected to have a huge impact on the market.

The underutilization of pulmonary function tests has been overcome by developing portable, hand-held, and user-friendly spirometry devices. For instance, in January 2020, NuvoAir’s connected spirometer received U.S. FDA approval for sale across the country. The device is designed for indications such as COPD, asthma, and cystic fibrosis.

Additionally, the integration of artificial intelligence evaluation of spirometry data to find effective treatment options for respiratory diseases drives the growth of the market.

• For instance, in March 2023, Clario teamed up with ArtiQ to enhance the reliability of spirometry data in respiratory clinical trials. Through this partnership, access to AI-driven reviews of spirometry data collected on the Clario Platform would be facilitated, bolstering confidence in trial outcomes.

Thus, constant innovations are one of the growth factors responsible for driving market growth.

Rising Prevalence of COPD to Propel Product Sales

COPD is the third leading cause of death globally and presents a significant burden on patients and health services. According to an article published by the National Heart, Lung, and Blood Institute in March 2022, COPD is the leading cause of death in the U.S., affecting about 16 million Americans. The major risk factor for COPD includes tobacco smoking. However, other environmental exposures, such as air pollution and biomass fuel exposure, may also contribute to severe health implications. The increasing prevalence of the disorder is an alarming situation worldwide that is expected to propel the demand for diagnostic devices during the forecast period.

RESTRAINING FACTORS

Dearth of Skilled Professionals May Limit Device Adoption

Despite the high prevalence of asthma and COPD globally, certain factors limit the adoption of these devices. Among them, the lack of a skilled workforce for conducting diagnostic tests is anticipated to restrain market growth. Pulmonary function testing is a series of different breathing tests that trained pulmonary function technologists can lead. However, there is a shortage of skilled healthcare professionals in developing countries. The immigration of healthcare workers to developed countries is the main reason for this shortage. The tendency to migrate to higher economic countries is primarily owing to the search for better wages and working conditions.

According to an article published by the World Health Organization (WHO) in July 2023, it is estimated that there will be a shortfall of 10 million health workers by 2030, especially in low-and lower-middle-income countries. This, coupled with other factors, such as the closure of PFT labs and diagnostic centers during the COVID-19 outbreak and limited awareness in underdeveloped countries, is anticipated to hamper the market growth.

However, addressing this shortage by investing in training programs and incentivizing individuals to enter the field of respiratory diagnostics is essential for unlocking the full potential of the spirometer market. This is also vital for improving respiratory health outcomes worldwide.

Spirometer Market Segmentation Analysis

By Product Type Analysis

Higher Adoption of Devices Due to Rising Need for Diagnostic Test Led to its Dominance

On the basis of product type, the market is divided into devices, software, and accessories & consumables.

The global market is witnessing significant technological advancements with an aim to improve testing capabilities, which has led to an increased demand for advanced devices. Moreover, start-ups and key players have started investing in the market to develop devices for effective management of respiratory diseases which led to dominance of devices segment.

 For example, in January 2023, Aluna, a company focused on developing solutions for asthma management, received USD 15.3 million in Series B funding to continue growing its solution among doctors and patients managing asthma, cystic fibrosis, and COPD. This is expected to increase the spirometry devices' product sales and market value.

In addition, the new product launches by key players in the spirometer device segment propels the growth of the market.

• For instance, in February 2023, Vitalograph launched the VitaloPFT Pulmonary Function Testing Series for advancements in respiratory diagnostic solutions to hospitals.

The software segment is anticipated to showcase significant growth during the forecast period due to the launch of advanced software solutions to manage testing procedures. Furthermore, due to the COVID-19 pandemic, the customer base has approached the online platform to manage spirometry testing, thus expanding the size of the software segment.

The accessories & consumables segment is anticipated to have a considerable share in the market during the forecast period owing to the reusability of the devices, leading to higher demand for accessories such as tubes, syringes, and filters.

By Type Analysis

Volume Measurement Segment Dominated due to Capability of Producing Accurate Results

On the basis of type, the market is segmented into volume measurement and peak flow meters.

The volume measurement segment held a dominant share in the market in 2023. The dominance can be attributed to its characteristic of producing accurate results with ease of handling the device. The volume measurement segment is projected to register a higher CAGR than peak flow meters during the forecast period due to the increasing application of the devices in asthma, cystic fibrosis, and others. In addition, the high adoption of spirometry devices for volume measurements has led to increased product sales.

To know how our report can help streamline your business, Speak to Analyst

The peak flow meters segment is expected to grow at a significant CAGR during the forecast period due to the increasing number of market players engaged in introducing advanced devices such as wireless spirometers in the global market. For example, in March 2021, DKSH Business Unit Healthcare and Smart Respiratory Products, a London-based digital healthcare company, announced a strategic collaboration to bring Smart Peak Flow, a compact digital peak expiratory flow meter (PEFM), to asthmatic patients in Asia.

Furthermore, increasing approvals by regulatory bodies for peak flow meters boost the growth of the segment.

• For instance, in January 2024, NuvoAir Medical received the U.S. FDA 510(k) clearance for their Air Next Spirometer. The device can be used at home for patients with conditions such as COPD, asthma, or ALS.

By Application Analysis

Growing Occurrence of Chronic Obstructive Pulmonary Disorder to Foster Segment Growth

Based on application, the market is segmented into chronic obstructive pulmonary disorder (COPD), asthma, and others.

The high prevalence of COPD globally and the increasing incidence of pulmonary infection among patients are some of the major factors responsible for the COPD segment dominance in 2023. According to a study published by the Thorax Journal in March 2021, individuals with exposure to inhalation of high doses of pesticides have a higher incidence of respiratory symptoms, airway obstruction, and COPD. Furthermore, the rising prevalence of COPD in developed and emerging countries led to the increased adoption of spirometers in the market for diagnostics purposes.

• For instance, according to the American Lung Association, 11.7 million adults in the U.S. will be diagnosed with COPD in 2022.

These devices are now being tested in labs to widen their application for cystic fibrosis and other pulmonary disorders. This factor is expected to contribute to the growth of the others segment during the forecast period.

By End User Analysis

Hospital Segment to Dominate Owing to Increasing Healthcare Expenditure

In terms of end user, the market is segmented into hospitals, diagnostic centers, homecare settings, physician/primary care offices or clinics, and other facilities.

The hospitals segment is set to dominate the global spirometer market share during the forecast period. The dominance can be attributed to the increasing healthcare expenditure leading to the adoption of advanced pulmonary function testing devices. For example, the National Healthcare Expenditure in the U.S. grew by 2.7% to USD 4.3 trillion in 2021, and hospital expenditure grew by 4.4% to USD 1,323.9 billion in 2021.

The clinics segment is expected to grow at a significant CAGR during the forecast period due to the increase in the number of stand-alone respiratory clinics in developed and emerging countries.

The diagnostic centers segment recorded a considerable share in the market in 2023 owing to rising patient preference for having lung function tests at the nearby diagnostic center. This has leveraged the adoption of hand held devices by the centers, leading to higher sales.

During the unprecedented times of COVID-19, home healthcare was one of the best services available at the doorstep. The homecare settings segment is expected to register significant growth by the end of the forecast period due to patients' rising preference shift from hospital to homecare settings. In January 2023, Koneksa launched a clinical trial study with an aim to assess the efficacy of at-home mobile spirometry utilizing digital biomarkers against traditional in-clinic spirometry for patients with moderate asthma undergoing long-acting beta-agonist therapy. Such initiatives are expected to propel the market expansion.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The market size in North America stood at USD 308.5 million in 2023. The dominance of this region can be attributed to the increasing prevalence of COPD, asthma, and other respiratory diseases. This has caused an increasing economic burden on the healthcare system, leading to development of precise devices to overcome the issue. For instance, as per the Global Initiative for Chronic Obstructive Lung Disease 2023 report, COPD is one of the top three causes of death worldwide, and 90% of these deaths occur in low and middle-income countries. The disease is exerting a huge burden on healthcare. For example, according to an article published by the American Family Physician in March 2023, asthma and COPD affect more than 40 million Americans and is the fourth leading cause of death in the U.S. The widespread occurrence of the disease is anticipated to surge demand for diagnostic devices. The presence of major players in the region has further contributed to the dominance of North America. This, along with the presence of adequate regulatory policies in the U.S. and Canada, is responsible for the region's dominance in the global market.

To know how our report can help streamline your business, Speak to Analyst

Europe market is projected to grow at a significant CAGR during the forecast period owing to the growing product approvals by healthcare bodies. Government bodies are taking initiatives to increase awareness about respiratory diseases to increase the number of patients undergoing diagnostic tests.

The Asia Pacific market is anticipated to showcase exponential growth during the forecast period owing to the increasing number of companies entering the untapped Asian economies. In addition, market players in this region are making heavy investments, which is expected to fuel demand for advanced products. For instance, in March 2021, VYAIRE launched AioCare, a remote mobile spirometer system in more than 15 countries including Australia.

• In November 2021, Cipla launched Spirofy in India, a wireless, portable device that performs lung function tests outdoors in remote areas. It is used for the diagnosis of COPD and asthma.

Latin America and the Middle East & Africa regions accounted for a comparatively lower share than other regions in the market in 2022. However, many public and private organizations are introducing campaigns and training programs to upscale the count of skilled healthcare professionals for diagnostics. For instance, the Pan African Thoracic Society (PATS) has been building spirometry capacity through the training, mentorship, and technical support of 482 healthcare professionals across 13 African countries from 2017 to 2021.

List of Key Companies in Spirometer Market

Increasing Focus on Technological Development by Major Companies to Strengthen Market Growth

The market is consolidated owing to the diverse product portfolio and remarkable distribution network of major companies in developed and emerging countries. Companies such as ndd Medizintechnik AG and COSMED srl, and others have introduced exemplary products in the market. However, the potential to leverage opportunities provided by the market is expected to enable the entry of several domestic players in the forthcoming years. Strategic partnerships among the key players to launch portable spirometers in the region are likely to contribute to the growth of the market. For instance, in January 2020, NuvoAir and Roche Italy partnered to manufacture portable devices for cystic fibrosis.

The other key players, such as MGC Diagnostics, Morgan Scientific, SCHILLER, VYAIRE Medical, and others, have also entered the market with novel advanced spirometry devices, software, and others.

LIST OF KEY COMPANIES PROFILED:

• ndd Medizintechnik AG (Switzerland)


• COSMED srl (Italy)


• MGC Diagnostics Corporation (U.S.)


• Morgan Scientific (U.S.)


• Chest M.I., Inc. (Japan)


• VYAIRE (U.S.)


• Ganshorn Medizin Electronic GmbH (Germany)


• Medical International Research (MIR) (Italy)

KEY INDUSTRY DEVELOPMENTS:

• March 2023: Clario partnered with technology startup ArtiQ to integrate its A.I. into clinical trial data collection for spirometry.


• January 2023: CAIRE Inc., an NGK SPARK PLUG CO., LTD. subsidiary, acquired MGC Diagnostics Holdings, Inc. (MGC) to strengthen its non-invasive cardiorespiratory diagnostics systems portfolio. MGC has a broad portfolio, which includes pulmonary function testing systems, cardiopulmonary exercise systems, spirometers, flow sensors, gas analyzers, and associated consumables.


• September 2022: RxCap, Inc. teamed up with ZEPHYRx LLC to combine ZEPHYRx's cloud spirometry platform with RxCap's remote monitoring platform.


• August 2022: AstraZeneca India partnered with Alveofit, a SaaS-IoT-enabled respiratory healthcare platform. This partnership aims to offer IoT-enabled handheld spirometers at hospitals across India.


• July 2022: Spirometry Diagnostic Units (CliniCabins) were introduced at the  Rochford Community Hospital and Kestrel House in Chelmsford. These units aim to enhance respiratory care services for the communities in mid and South Essex by offering specialized diagnostic support and clinical assessment for patients with respiratory conditions.


• June 2021: ERT launched ERT iSpiro Virtual Visits, which enables real-time coaching during at-home pulmonary function tests (PFT). With iSpiro Virtual Visits, ERT delivers on its commitment to offer customer and patient-oriented innovations that enable decentralization.


• September 2020: Midmark Corp. launched the Midmark Digital Spirometer, intended to make the detection and management of asthma, COPD, and other respiratory illnesses simple and effective.

REPORT COVERAGE

An Infographic Representation of Spirometers Market

View Full Infographic

To get information on various segments, share your queries with us

The research report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product types, and leading product applications. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the advanced market over the recent years.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation